Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: A case-control study

Zsuzsanna Kahán, János Gardi, Tibor Nyári, Imre Földesi, Rozália Hajnal-Papp, Katalin Ormándi, György Lázár, László Thurzó, Andrew V Schally

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

There is increasing evidence that different types of breast cancers are related to distinct risk factors. We analyzed the risk of breast cancer with respect to circulating insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3, 17β-estradiol, estrone, testosterone, androstenedione and sex hormone-binding globulin (SHBG), taking into consideration the characteristics of the tumors. Plasma hormone levels of 102 postmenopausal patients with breast cancer detected by mammography screening, and 102 matched controls were analyzed in relation to the histological type, the status of the estrogen receptor (ER), the progesterone receptor (PR) and the HER2 in the tumors. Significant positive associations were revealed between the IGF-I concentration and the overall risk of breast cancer (OR=3.1,95% CI: 1.5-6.2), ER+PR+ breast cancer (OR=2.4,95% CI: 1.1-5.4) and ER+PR-breast cancer (OR=4.3, 95% CI: 1.2-14.3) when the highest and the lowest ranges of IGF-I were compared. Significant associations were also found between the highest and the lowest quartiles of testosterone, resulting in OR=4.1 (95% CI: 1.8-9.4) for the risks of breast cancer and OR=5.8 (96% CI: 2.1-16.2) of ER+PR+ breast cancer. A synergy was seen between IGF-I and testosterone levels. When both plasma IGF-I and testosterone were in the highest quartile ranges, an OR=26.4 (95% CI: 1.6-426.5, p=0.021) was computed for breast cancer overall. No significant synergistic effects could be demonstrated with other parameters. There were significant, 2.5-fold (95% CI: 1.2-5.6), and 16-fold (95% CI: 2.0-133.5) increases in the overall risks of breast cancer and of ER+PR-breast cancer, respectively, when the highest and the lowest quartiles of IGFBP-3 were compared. No associations were found between any of the hormones and the risk of ER-PR-tumors. The increased prevalence of ER+ breast cancers in patients with higher levels of IGF-I, IGFBP-3 or testosterone implicate these hormones in the etiology of hormone-dependent breast cancer. Additional analyses specific for breast cancer subtypes may shed light on the value of hormone determinations for tailored chemoprevention.

Original languageEnglish
Pages (from-to)193-200
Number of pages8
JournalInternational Journal of Oncology
Volume29
Issue number1
StatePublished - Jul 1 2006

Fingerprint

Globulins
Somatomedins
Insulin-Like Growth Factor I
Testosterone
Case-Control Studies
Hormones
Breast Neoplasms
Estrogen Receptors
Progesterone Receptors
Insulin-Like Growth Factor Binding Protein 3
Neoplasms
Sex Hormone-Binding Globulin
Androstenedione
Estrone
Chemoprevention
Mammography
Estradiol

Keywords

  • Breast cancer risk
  • Breast cancer subtypes
  • Estrogen receptor
  • HER2
  • Progesterone receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women : A case-control study. / Kahán, Zsuzsanna; Gardi, János; Nyári, Tibor; Földesi, Imre; Hajnal-Papp, Rozália; Ormándi, Katalin; Lázár, György; Thurzó, László; Schally, Andrew V.

In: International Journal of Oncology, Vol. 29, No. 1, 01.07.2006, p. 193-200.

Research output: Contribution to journalArticle

Kahán, Zsuzsanna ; Gardi, János ; Nyári, Tibor ; Földesi, Imre ; Hajnal-Papp, Rozália ; Ormándi, Katalin ; Lázár, György ; Thurzó, László ; Schally, Andrew V. / Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women : A case-control study. In: International Journal of Oncology. 2006 ; Vol. 29, No. 1. pp. 193-200.
@article{e9e414f3bfe141aebd44b08a8dd0ec8c,
title = "Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: A case-control study",
abstract = "There is increasing evidence that different types of breast cancers are related to distinct risk factors. We analyzed the risk of breast cancer with respect to circulating insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3, 17β-estradiol, estrone, testosterone, androstenedione and sex hormone-binding globulin (SHBG), taking into consideration the characteristics of the tumors. Plasma hormone levels of 102 postmenopausal patients with breast cancer detected by mammography screening, and 102 matched controls were analyzed in relation to the histological type, the status of the estrogen receptor (ER), the progesterone receptor (PR) and the HER2 in the tumors. Significant positive associations were revealed between the IGF-I concentration and the overall risk of breast cancer (OR=3.1,95{\%} CI: 1.5-6.2), ER+PR+ breast cancer (OR=2.4,95{\%} CI: 1.1-5.4) and ER+PR-breast cancer (OR=4.3, 95{\%} CI: 1.2-14.3) when the highest and the lowest ranges of IGF-I were compared. Significant associations were also found between the highest and the lowest quartiles of testosterone, resulting in OR=4.1 (95{\%} CI: 1.8-9.4) for the risks of breast cancer and OR=5.8 (96{\%} CI: 2.1-16.2) of ER+PR+ breast cancer. A synergy was seen between IGF-I and testosterone levels. When both plasma IGF-I and testosterone were in the highest quartile ranges, an OR=26.4 (95{\%} CI: 1.6-426.5, p=0.021) was computed for breast cancer overall. No significant synergistic effects could be demonstrated with other parameters. There were significant, 2.5-fold (95{\%} CI: 1.2-5.6), and 16-fold (95{\%} CI: 2.0-133.5) increases in the overall risks of breast cancer and of ER+PR-breast cancer, respectively, when the highest and the lowest quartiles of IGFBP-3 were compared. No associations were found between any of the hormones and the risk of ER-PR-tumors. The increased prevalence of ER+ breast cancers in patients with higher levels of IGF-I, IGFBP-3 or testosterone implicate these hormones in the etiology of hormone-dependent breast cancer. Additional analyses specific for breast cancer subtypes may shed light on the value of hormone determinations for tailored chemoprevention.",
keywords = "Breast cancer risk, Breast cancer subtypes, Estrogen receptor, HER2, Progesterone receptor",
author = "Zsuzsanna Kah{\'a}n and J{\'a}nos Gardi and Tibor Ny{\'a}ri and Imre F{\"o}ldesi and Roz{\'a}lia Hajnal-Papp and Katalin Orm{\'a}ndi and Gy{\"o}rgy L{\'a}z{\'a}r and L{\'a}szl{\'o} Thurz{\'o} and Schally, {Andrew V}",
year = "2006",
month = "7",
day = "1",
language = "English",
volume = "29",
pages = "193--200",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women

T2 - A case-control study

AU - Kahán, Zsuzsanna

AU - Gardi, János

AU - Nyári, Tibor

AU - Földesi, Imre

AU - Hajnal-Papp, Rozália

AU - Ormándi, Katalin

AU - Lázár, György

AU - Thurzó, László

AU - Schally, Andrew V

PY - 2006/7/1

Y1 - 2006/7/1

N2 - There is increasing evidence that different types of breast cancers are related to distinct risk factors. We analyzed the risk of breast cancer with respect to circulating insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3, 17β-estradiol, estrone, testosterone, androstenedione and sex hormone-binding globulin (SHBG), taking into consideration the characteristics of the tumors. Plasma hormone levels of 102 postmenopausal patients with breast cancer detected by mammography screening, and 102 matched controls were analyzed in relation to the histological type, the status of the estrogen receptor (ER), the progesterone receptor (PR) and the HER2 in the tumors. Significant positive associations were revealed between the IGF-I concentration and the overall risk of breast cancer (OR=3.1,95% CI: 1.5-6.2), ER+PR+ breast cancer (OR=2.4,95% CI: 1.1-5.4) and ER+PR-breast cancer (OR=4.3, 95% CI: 1.2-14.3) when the highest and the lowest ranges of IGF-I were compared. Significant associations were also found between the highest and the lowest quartiles of testosterone, resulting in OR=4.1 (95% CI: 1.8-9.4) for the risks of breast cancer and OR=5.8 (96% CI: 2.1-16.2) of ER+PR+ breast cancer. A synergy was seen between IGF-I and testosterone levels. When both plasma IGF-I and testosterone were in the highest quartile ranges, an OR=26.4 (95% CI: 1.6-426.5, p=0.021) was computed for breast cancer overall. No significant synergistic effects could be demonstrated with other parameters. There were significant, 2.5-fold (95% CI: 1.2-5.6), and 16-fold (95% CI: 2.0-133.5) increases in the overall risks of breast cancer and of ER+PR-breast cancer, respectively, when the highest and the lowest quartiles of IGFBP-3 were compared. No associations were found between any of the hormones and the risk of ER-PR-tumors. The increased prevalence of ER+ breast cancers in patients with higher levels of IGF-I, IGFBP-3 or testosterone implicate these hormones in the etiology of hormone-dependent breast cancer. Additional analyses specific for breast cancer subtypes may shed light on the value of hormone determinations for tailored chemoprevention.

AB - There is increasing evidence that different types of breast cancers are related to distinct risk factors. We analyzed the risk of breast cancer with respect to circulating insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3, 17β-estradiol, estrone, testosterone, androstenedione and sex hormone-binding globulin (SHBG), taking into consideration the characteristics of the tumors. Plasma hormone levels of 102 postmenopausal patients with breast cancer detected by mammography screening, and 102 matched controls were analyzed in relation to the histological type, the status of the estrogen receptor (ER), the progesterone receptor (PR) and the HER2 in the tumors. Significant positive associations were revealed between the IGF-I concentration and the overall risk of breast cancer (OR=3.1,95% CI: 1.5-6.2), ER+PR+ breast cancer (OR=2.4,95% CI: 1.1-5.4) and ER+PR-breast cancer (OR=4.3, 95% CI: 1.2-14.3) when the highest and the lowest ranges of IGF-I were compared. Significant associations were also found between the highest and the lowest quartiles of testosterone, resulting in OR=4.1 (95% CI: 1.8-9.4) for the risks of breast cancer and OR=5.8 (96% CI: 2.1-16.2) of ER+PR+ breast cancer. A synergy was seen between IGF-I and testosterone levels. When both plasma IGF-I and testosterone were in the highest quartile ranges, an OR=26.4 (95% CI: 1.6-426.5, p=0.021) was computed for breast cancer overall. No significant synergistic effects could be demonstrated with other parameters. There were significant, 2.5-fold (95% CI: 1.2-5.6), and 16-fold (95% CI: 2.0-133.5) increases in the overall risks of breast cancer and of ER+PR-breast cancer, respectively, when the highest and the lowest quartiles of IGFBP-3 were compared. No associations were found between any of the hormones and the risk of ER-PR-tumors. The increased prevalence of ER+ breast cancers in patients with higher levels of IGF-I, IGFBP-3 or testosterone implicate these hormones in the etiology of hormone-dependent breast cancer. Additional analyses specific for breast cancer subtypes may shed light on the value of hormone determinations for tailored chemoprevention.

KW - Breast cancer risk

KW - Breast cancer subtypes

KW - Estrogen receptor

KW - HER2

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=33749025469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749025469&partnerID=8YFLogxK

M3 - Article

C2 - 16773200

AN - SCOPUS:33749025469

VL - 29

SP - 193

EP - 200

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -